Icatibant Stada

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with confirmed diagnosis.

GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution, ensuring reliable delivery across multiple continents.

Icatibant is used to treat conditions driven by excessive bradykinin activity, primarily hereditary angioedema. - Hereditary angioedema type I: rapid relief of swelling during acute attacks. - Hereditary angioedema type II: rapid relief of swelling during acute attacks. - Hereditary angioedema with normal C1‑inhibitor: rapid relief of swelling during acute attacks.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Nausea: occasional feeling of queasiness. - Headache: transient head discomfort. - Dizziness: brief episodes of light‑headedness. - Swelling at injection site: mild localized edema.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Urticaria: widespread hives or skin rash. - Angioedema of other sites: unexpected swelling of lips, tongue, or airway. - Hypotension: sudden drop in blood pressure. - Severe injection‑site necrosis: tissue death at the injection area. - Hypersensitivity reactions: fever, chills, or systemic rash.

Before using Icatibant, consider the following safety measures. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion; weigh benefits against possible infant exposure. - Renal impairment: no dosage adjustment required, but monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for angioedema. - Estrogen‑containing therapies: may affect HAE severity; monitor clinical response. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effects may raise angioedema risk. - Angiotensin receptor blockers: similar potential for increased bradykinin‑mediated reactions. - Other bradykinin B2 antagonists: no added therapeutic benefit and may increase adverse events.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may modify HAE attack frequency. - Diuretics: monitor fluid balance and blood pressure. - Immunosuppressants: observe for heightened infection susceptibility.